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Neonates have long been a vulnerable pop-
ulation to unstudied therapies, starting
as early as the late nineteenth century
with Mrs. Winslow’s Soothing Syrup, a
purported remedy for teething that con-
tained alcohol and morphine sulfate, caus-
ing numerous infant deaths (1). In 1959,
Gray baby syndrome was first reported in
infants receiving large doses of chloram-
phenicol as a broad spectrum antibacterial
agent (2), and in 1983, Mulhall et al. (3)
noted the altered pharmacokinetics (PK)
of chloramphenicol in neonates and young
infants resulting in elevated serum levels
and some toxic effects.
During the last 50 years, we have
witnessed amazing progress in neona-
tal care resulting in increased survival
and improved outcomes for 23–24 weeks
preterm infants and decreased morbidity
and mortality associated with many neona-
tal diseases including primary pulmonary
hypertension of the newborn (PPHN) and
hypoxic ischemic encephalopathy (HIE).
This progress has been buttressed by the
development of therapies such as surfac-
tant, nitric oxide, caffeine, and the Cool
Cap, all of which are FDA labeled for
use in the neonatal population. However,
neonates are still exposed to a signifi-
cant number of off-label medications dur-
ing their hospitalization. Warrier et al.
(4) reported that infants <28 weeks ges-
tation were exposed to a mean of almost
12 drugs during their hospitalization, and
Conroy and McIntyre (5) demonstrated
that 93% of babies received at least one
unlicensed or off-label medication during
their hospitalization. A 2014 American
Academy of Pediatrics Policy Statement
acknowledged that off-label use of drugs,
“presents an even larger and more complex
issue in preterm and full term neonates”
(6). Exposure to off-label drugs is only one
side of the coin, as the subspecialty con-
tinues to lack sufficient new therapeutic
interventions to treat most of the neonatal
specific diseases.
Legislative mandates have encouraged
studies in pediatric populations. Congress
passed pediatric legislation under the Food
and Drug Administration Modernization
Act of 1997, which was followed by the Best
Pharmaceuticals for Children Act (BPCA)
in 2002 and the Pediatric Research Equity
Act (PREA) in 2003. Both BPCA and
PREA were made permanent under the
Food and Drug Administration Safety and
Innovation Act (FDASIA) in 2012 (7). A
number of studies submitted in response
to the pediatric legislative initiatives have
included neonatal information for seda-
tion, gastroesophageal reflux disease, drugs
used in surgery (adjunct to general anes-
thesia, reversal of non-depolarizing neu-
romuscular agents), thrombosis with sys-
temic to pulmonary artery shunts, head
lice (safety information related to ben-
zyl alcohol exposure), prevention of bron-
chopulmonary dysplasia (BPD), treatment
of mild/moderate pain or fever, and HIV
infection (8).
Despite efforts promoted by the legis-
lation, the majority of these studies were
not able to establish efficacy in the neona-
tal population. It is not clear whether
the lack of efficacy is accurate or is
related to study design issues including the
study population, disease characteristics in
the neonate, drug properties (dose, tissue
effect, metabolism), or the inability of the
endpoints to reflect clinically meaningful
outcomes. Each of these areas needs to be
addressed in future studies.
Future studies will need to carefully
define the study populations. In an effort
to maximize the number of study partici-
pants, many studies in preterm infants have
included all infants born at <32 weeks ges-
tation. A 4-week-old infant that was born
at 24 weeks gestation is not the same as
a 1-day-old born at 28 weeks gestation.
The normal ontogenic processes in utero
are disrupted by birth and postnatal care
including exposure to a relatively hyperoxic
environment (even in room air) with major
changes in organ perfusion and alterations
in nutrient/mineral delivery. As an exam-
ple, it is not possible to achieve third
trimester rates of calcium accretion in the
preterm infant (9). A more precise defin-
ition of the inclusion criteria for studies,
taking into consideration both gestational
age and postnatal age, will potentially iden-
tify more homogeneous groups for studies
and may be more accurate in the findings of
safety and efficacy because the populations
will be more appropriately matched.
Disease characteristics in the neonatal
population are dependent on the gesta-
tional age at birth and the postnatal age
of the infant. Surfactant has been shown
to be a very effective therapy for respi-
ratory distress syndrome but the degree
of response may differ between gestational
ages based on the development of the pul-
monary architecture (10, 11). It is critically
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important to understand the pathophysiol-
ogy of neonatal disease processes, not just
at the time of birth but with respect to post-
natal adaptive responses. This is especially
true with respect to safety and understand-
ing potential off-target effects of drugs in
the developing neonate.
There are a number of examples of
altered PK for drugs used in neonates
including chloramphenicol (3), gentam-
icin (12), and most recently clindamycin
(13). Drug elimination may even be faster
in small preterm neonates and the dose
requirement may be as much as triple that
of the adults as seen in the publication
on micafungin (14). It will be impera-
tive to understand receptor and enzyme
system ontogeny as well as perturbations
due to postnatal changes when infants
are born at various gestational ages from
24 weeks to full term. This has implica-
tions for absorption, distribution, metab-
olism, and excretion of drugs and is criti-
cally important for individual drug dosing
but also for the development of physio-
logically based pharmacokinetic (PBPK)
models to enhance optimal drug dosing
for neonates. Formulation issues continue
to plague neonatal drugs and will need to
be addressed to ensure consistency in drug
delivery and exposure.
Clinical trials are challenging in the
neonatal population and will require inno-
vative approaches leveraged from the rare
disease experience (15). These efforts may
include the use of master protocols (16)
with innovative adaptive designs using a
limited number of doses that are based on
modeling and simulation efforts derived
from data obtained through opportunis-
tic sampling. Safety monitoring must be
a priority and will need to be differentiated
from confounding disease processes and
concomitant medication exposure. Clini-
cally meaningful endpoints will need to
be developed by the neonatal community,
and predictive and prognostic biomarkers
should be developed to enrich trial popu-
lations. In 2010, the Center for Drug Eval-
uation and Research (CDER) established
the Drug Development Tools (DDT) Qual-
ification programs as part of the Criti-
cal Path Initiative to provide a framework
for development and regulatory acceptance
of scientific tools, including biomarkers,
animal models for use under the Animal
Rule, and clinical outcome assessments for
use in drug development. The qualifica-
tion decision will be made publicly avail-
able and qualified DDTs will allow drug
developers to use the DDT in the quali-
fied context of use without requesting that
CDER reconsider and reconfirm the suit-
ability of the DDT for the qualified con-
text of use. Carefully designed biomark-
ers and endpoints will be the hallmark
of studies for neonatal diseases (7). These
novel approaches to neonatal clinical trials
should be highlighted by current training
programs.
As an adjunct to these clinical trial ques-
tions, it is critical that the data from these
trials be in a format that permits cross-
study analyses. In addition, enormous
quantities of information are accrued on
a daily basis on infants in the NICU. Some
of this is captured in registries and some in
electronic health records. These data may
not be represented in a standardized way
so that analyses are not possible across sys-
tems. This wealth of information from clin-
ical trials, registries, and electronic health
records should be mined to optimize study
designs and to capture safety information
but needs to be transformed and standard-
ized to maximize comparative efforts.
As John Donne coined, “No Man is an
Island” and these issues cannot be tack-
led by individuals alone. The neonatal
community needs to work collaboratively
to accomplish these difficult tasks. FDA’s
Critical Path Initiative was launched in
2004, with the release of the report enti-
tled, “Innovation/Stagnation: Challenge
and Opportunity on the Critical Path to
New Medical Products.” The report chal-
lenged the scientific community to work
together to bridge scientific gaps, enhance
translational sciences, and improve the
medical product development process.
Under the auspices of the Critical Path
Initiative, FDA has collaborated through
Public Private Partnerships (PPPs) with
multiple stakeholders, including other Fed-
eral, academic, scientific, patient advocacy,
and industry organizations, to facilitate the
development of new tools to foster inno-
vation in FDA-regulated product develop-
ment. These PPPs enable stakeholders to
leverage expertise and resources to con-
duct mutually beneficial research activi-
ties resulting in publicly available infor-
mation. The public health need to protect
neonates by affording them access to safe
and efficacious therapies provides the basis
for the development of a neonatal consor-
tium to address all of these complex issues.
It is imperative that the neonatal com-
munity work collaboratively to develop and
label drugs for neonatal diseases. Basic sci-
ence research,critical to defining the patho-
physiology of disease and the ontogeny
of metabolic pathways, provides the infra-
structure for innovative approaches to
studying drugs in neonates. The basic sci-
ence supports modeling and simulation
efforts to establish optimal dosage strate-
gies and promotes the development of
clinically meaningful short-term and long-
term endpoints that can be implemented
in innovative trial strategies. It is criti-
cally important that all sources of informa-
tion be leveraged and standardized in this
effort including data from clinical trials,
registries, and electronic health records. A
neonatal consortium effort would create a
forum to bring academic, industry, patient
advocacy, and government stakeholders
together to consolidate the approach to
maximize opportunities to label drugs for
use in neonates. The initial discussion
of a potential neonatal consortium, co-
sponsored by the Critical Path Institute,
Burroughs-Wellcome Fund, and FDA took
place on the FDA White Oak campus
on October 28 and 29, 2014. Hopefully,
this will launch a productive collabora-
tive effort to spur drug development for
neonates.
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